ImageneBio Inc (IMA)
ImageneBio Inc operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $5.61, down 1.92% on the session, giving a market capitalisation of $63.3M. On trailing twelve-month figures it carries a trailing P/E of -1.08, a net margin of 0.0%. Its beta of 0.76 implies it has historically moved less than the broad market.
ImageneBio Inc (IMA) is a biotechnology company with therapies currently undergoing human trials. The firm concentrates on creating innovative medical treatments for a variety of immune-related and inflammatory diseases. A key component of their pipeline is IMG-007, a non-depleting anti-OX40 monoclonal antibody, which is now in Phase 2b clinical studies targeting atopic dermatitis.
ImageneBio Inc is most often compared with the following Healthcare names: